Targeted metabolomics in bladder cancer: From analytical methods development and validation towards application to clinical samples

Mpanga, Arlette Yumba; Siluk, Danuta; Jacyna, Julia; Szerkus, Oliwia; Wawrzyniak, Renata; Markuszewski, Marcin; Matuszewski, Marcin; Kaliszan, Roman; Markuszewski, Michał J.

doi:10.1016/j.aca.2018.01.055

Cited by 26 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our research results are also consistent with those of Yumba Mpanga et al. [ 84 ], which indicated significantly higher levels of tryptophan in the urine of patients with HG BC compared to LG BC group.…”

Section: Discussionsupporting

confidence: 93%

Metabolomic and elemental profiling of blood serum in bladder cancer

Ossoliński

Ruman

Copié

et al. 2022

Journal of Pharmaceutical Analysis

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Metabolomic and elemental profiling of blood serum in bladder cancer

Ossoliński

Ruman

Copié

et al. 2022

Journal of Pharmaceutical Analysis

View full text Add to dashboard Cite

“…However, there are huge challenges, usually in the identification of whole metabolic profiling owing to the wide variety and dynamic range of metabolites. Researchers are now paying more attention to targeted metabolomics analysis which helps to improve the reliability and repeatability of results (Jerzak et al, 2017;Yumba Mpanga et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Identifying potential serum biomarkers of breast cancer through targeted free fatty acid profiles screening based on a GC–MS platform

Tan

Zhang

et al. 2020

Biomedical Chromatography

View full text Add to dashboard Cite

Recent advances suggest that abnormal fatty acid metabolism highly correlates with breast cancer, which provide clues to discover potential biomarkers of breast cancer. This study aims to identify serum free fatty acid (FFA) metabolic profiles and screen potential biomarkers for breast cancer diagnosis. Gas chromatography–mass spectrometry and our in‐house fatty acid methyl ester standard substances library were combined to accurately identify FFA profiles in serum samples of breast cancer patients and breast adenosis patients (as controls). Potential biomarkers were screened by applying statistical analysis. A total of 18 FFAs were accurately identified in serum sample. Two groups of patients were correctly discriminated by the orthogonal partial least squares–discriminant analysis model based on FFA profiles. Seven FFA levels were significantly higher in serum from breast cancer patients than that in controls, and exhibited positive correlation with malignant degrees of disease. Furthermore, five candidates (palmitic acid, oleic acid, cis‐8,11,14‐eicosatrienoic acid, docosanoic acid and the ratio of oleic acid to stearic acid) were selected as potential serum biomarkers for differential diagnosis of breast cancer. Our study will help to reveal the metabolic signature of FFAs in breast cancer patients, and provides valuable information for facilitating clinical noninvasive diagnosis.

show abstract

“…The abundance of hippuric acid was significantly decreased in thymoma compared to thymic hyperplasia, with fold change of −11.71 (negative mode) and −21.91 (positive mode) and p value of 0.0186 (Table 1 and Figures 3I and 3J), while it was significantly increased in the aggressive group compared to indolent thymomas (Figure 5E) ( p < 0.05). Hippuric acid was selected as a urine biomarker for colorectal, 36 bladder 37 and lung cancer, 38 and a decrease in plasma hippuric acid level was also found in breast cancer patients 39 . Hippuric acid could be produced from dietary protein catabolism and from quinic acid by gastrointestinal tract microflora 40 .…”

Section: Resultsmentioning

confidence: 99%

Ultrahigh‐performance liquid chromatography–high‐resolution mass spectrometry‐based plasma metabolomics study of thymoma and thymic hyperplasia

Zhang

Zang

Yang

et al. 2023

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

Rationale: Thymoma is a rare malignant tumor but it is the most common primary tumor of the anterior mediastinum. The current imaging methods for thymoma screening suffer from false positive rate problems, and thymoma pathogenesis remains elusive. Study of thymoma metabolic characteristics could provide clues for improving the diagnosis and understanding the pathogenesis of thymoma.Methods: Metabolic profiling of plasma from thymoma and thymic hyperplasia patients was performed using ultrahigh-performance liquid chromatography combined with high-resolution mass spectrometry in both positive and negative ionization modes. After pre-and post-processing, the dataset was divided into three age groups and statistical analysis was performed to select differential metabolites of thymoma. For feature identification, experimental tandem mass spectra were matched to those of databases and available chemical standards, and also manually annotated with plausible chemical structures to ensure high identification confidence.Results: A total of 47 differential metabolites were identified in thymoma.Significantly higher levels of histidine, sphinganine 1-phosphate, lactic acid dimer, phenylacetylglutamine, LPC (18:3) and LPC (16:1), and significantly lower levels of phenylalanine, indole-3-propionic acid (IPA), hippuric acid and mesobilirubinogen were associated with thymoma. Tryptophan level in thymoma-associated myasthenia gravis (TAMG) was significantly lower than that of the MG(À) group. IPA and hippuric acid abundances exhibited increasing trends from indolent to aggressive thymoma.Conclusions: Our study revealed aberrant aromatic amino acid metabolism and fatty acid oxidation might be associated with thymoma. The identified unique metabolic characteristics of thymoma may provide valuable information for study of the molecular mechanism of thymoma pathogenesis, and improvement of diagnosis and discovery of new therapeutic strategies for thymoma.

show abstract

Targeted metabolomics in bladder cancer: From analytical methods development and validation towards application to clinical samples

Cited by 26 publications

References 27 publications

Metabolomic and elemental profiling of blood serum in bladder cancer

Metabolomic and elemental profiling of blood serum in bladder cancer

Identifying potential serum biomarkers of breast cancer through targeted free fatty acid profiles screening based on a GC–MS platform

Ultrahigh‐performance liquid chromatography–high‐resolution mass spectrometry‐based plasma metabolomics study of thymoma and thymic hyperplasia

Contact Info

Product

Resources

About